Data from the BSRBR-RA study has influenced clinical guidelines.
Category: Rheumatoid Arthritis
BSRBR-RA Recruitment Workshop – 11th February 2025
We recently held a workshop for our NHS healthcare professional colleagues involved in the BSRBR-RA Study around the topic of Recruitment. We wanted to find out what really works in terms of recruiting participants to the study and to share good practice across...
Patient follow-up questionnaires
We recently launched our online system for collecting patient data. This is a new exciting development for us and we are thrilled that we have been able to start sending questionnaires to our study participants.How it worksThe participant consents to the study and...
The impact of your data
Have you ever wondered where the data you provide are used?Whether you are a participant in the study, or an NHS professional who provides the data to BSRBR-RA, the answer is the same. This data is vital in the ongoing research into the long-term safety of biologic,...
BSRBR-RA Review of 2024
2024 has been another great year for BSRBR-RA. We’re very grateful to the NHS professionals who provide data, and to the participants. The data provided is integral to the success of the research.Our year in numbersOur publications this year Association between body...
How body weight affects the way people with rheumatoid arthritis react to treatment with tocilizumab
Dr Simon Tsoi investigated the association between body weight and tocilizumab effectiveness in rheumatoid arthritis, using data from the BSRBR-RA study. The results were published in the Rheumatology journal. What was already known?Tocilizumab is a type of treatment...
Tyenne (tocilizumab) – the new biosimilar on the block
What is Tyenne? Tyenne is the first tocilizumab (interleukin-6) biosimilar that has recently been approved by the European Medicines Agency (EMA) for the treatment of moderate to severe rheumatoid arthritis in adults. It is now starting to be prescribed in the UK and...
Contact Us
+44 (0) 161 306 6000
Recent Comments